Chiauranib

DRUG16 trials

Sponsors

Chipscreen Biosciences, Ltd.

Conditions

Advanced Solid Malignant TumorChiauranibHealthy VolunteersHepatocellular CarcinomaMetastatic Pancreatic Ductal AdenocarcinomaNon-Hodgkin's LymphomaNon-hodgkin's LymphomaOvarian Cancer

Phase 1

Phase I Study of Chiauranib in Patients With Advanced Solid Tumors

CompletedNCT02122809

Chipscreen Biosciences, Ltd.Solid Tumors

Start: 2014-02-28End: 2016-06-30Updated: 2016-06-17

Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma

TerminatedNCT03074825

Chipscreen Biosciences, Ltd.Non-Hodgkin's Lymphoma

Start: 2017-05-09End: 2019-02-14Updated: 2019-07-24

Phase Ib Study of Chiauranib in Patients With Ovarian Cancer

CompletedNCT03166891

Chipscreen Biosciences, Ltd.Ovarian Cancer

Start: 2017-12-15End: 2019-03-20Updated: 2020-01-18

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

CompletedNCT03216343

Chipscreen Biosciences, Ltd.Small Cell Lung Cancer

Start: 2017-11-09End: 2023-05-15Updated: 2023-08-30

Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma

CompletedNCT03245190

Chipscreen Biosciences, Ltd.Hepatocellular Carcinoma

Start: 2018-04-28End: 2019-11-01Updated: 2021-06-18

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

CompletedNCT03974243

Chipscreen Biosciences, Ltd.Non-hodgkin's Lymphoma

Start: 2019-07-11End: 2021-12-31Updated: 2022-03-09

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

RecruitingNCT05271292

Chipscreen Biosciences, Ltd.Advanced Solid Malignant Tumor, Small Cell Lung Cancer

Start: 2022-08-26End: 2025-05-31Target: 36Updated: 2024-07-16

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

CompletedNCT05346601

Chipscreen Biosciences, Ltd.Healthy Volunteers

Start: 2022-06-02End: 2022-06-28Updated: 2023-02-09

Phase 2

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

CompletedNCT03901118

Chipscreen Biosciences, Ltd.Ovarian Cancer

Start: 2019-07-01End: 2020-12-18Updated: 2021-03-19

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

TerminatedNCT05336721

Chipscreen Biosciences, Ltd.Triple-negative Breast Cancer

Start: 2021-11-05End: 2024-11-05Updated: 2025-03-24

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

CompletedNCT05497843

Chipscreen Biosciences, Ltd.Soft Tissue Sarcoma

Start: 2022-08-25End: 2025-01-03Updated: 2025-04-03

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT06492915

Chipscreen Biosciences, Ltd.Pancreatic Ductal Adenocarcinoma

Start: 2024-08-13End: 2026-10-31Target: 42Updated: 2026-03-18

Phase 3

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

CompletedNCT04830813

Chipscreen Biosciences, Ltd.Small Cell Lung Cancer

Start: 2021-03-05End: 2024-04-01Updated: 2024-12-09

Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

RecruitingNCT04921527

Chipscreen Biosciences, Ltd.Chiauranib, Ovarian Cancer, Paclitaxel +1

Start: 2021-12-20End: 2025-07-31Target: 454Updated: 2024-10-18

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruitingNCT07445295

Chipscreen Biosciences, Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2026-03-31End: 2028-11-30Target: 558Updated: 2026-03-03

Unknown Phase

Mass Balance Study of [14C]Chiauranib

CompletedNCT05371899

Chipscreen Biosciences, Ltd.Small Cell Lung Cancer

Start: 2022-07-20End: 2024-03-18Updated: 2024-07-15

Related Papers

Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study.

2024-08-094 citations

Abstract CT157: An exploratory phase 2 study of chiauranib monotherapy for small cell lung cancer after two or more lines of previous therapy

Cancer Research2021-07-012 citations

Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.

2019-01-1429 citations